• LEARN MORE ABOUT KEYNOTE 695
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact
OncoSec Medical Incorporated
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact

Press Releases

Investors

Investors

  • Overview
    • Profile
    • Contacts
  • Events & Presentations
  • Analysts
  • Press Releases
    • Email Alerts
  • Financial Info
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • FAQ
  • Press Releases

  • Email Alerts

OncoSec Releases Presentation Spotlighting the Benefits of the Proposed CGP/Sirtex Transaction and Partnership

Dec 20, 2019 9:00am EST

OncoSec to Receive Approximately $885,000 Through New Jersey Technology Business Tax (NOL) Program

Dec 16, 2019 8:30am EST

OncoSec Presents Interim Data of 28.5% Objective Response Rate (ORR) from Ongoing KEYNOTE-890 Study Evaluating TAVO™ in Combination with KEYTRUDA® for Heavily Pretreated, Late-Stage, Metastatic Triple Negative Breast Cancer (mTNBC) at the 2019 San Antonio Breast Cancer Symposium

Dec 13, 2019 8:30am EST

OncoSec CEO Sends Letter to Fellow Shareholders

Dec 12, 2019 8:30am EST

OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value

Dec 09, 2019 8:30am EST

OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO™ and KEYTRUDA® in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

Dec 05, 2019 8:30am EST

OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing

Dec 04, 2019 9:00am EST

OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements

Dec 02, 2019 8:00am EST

OncoSec to Present at the 31st Annual Piper Jaffray Healthcare Conference

Nov 26, 2019 8:30am EST

OncoSec Presents Immunological Data Associated with Positive Tumor Response from TAVO™ KEYNOTE Studies Evaluating Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Nov 12, 2019 8:30am EST
RSS
  • Prev
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...46
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    logo

    Sign Up for our mailing list to stay current on all of our exciting new research and developments.

    Get Email Alerts
    OncoSec’s investigational products have not been approved or cleared by the FDA.

    Links

    • About
    • Pipeline
    • Technology
    • Partnering
    • Patients
    • Media
    • Investors
    • Contact
    • KEYNOTE 695 CLINICAL TRIAL

    Contact

    New Jersey Headquarters
    820 Bear Tavern Road
    Suite 200
    Ewing, NJ 08628

    R&D Laboratories
    3565 General Atomics Court #100
    San Diego, CA 92121

    p | 855.662.6732
    f | 858.430.3832

    Investors@OncoSec.com


    © 2023 OncoSec Medical Incorporated. All Rights Reserved. Q12-003052-01 REV E.